Difference between revisions of "Team:UC Davis/Collaborations"

(made eligible, ready for samir to edit)
 
Line 1: Line 1:
 
{{UC_Davis}}
 
{{UC_Davis}}
 
<html>
 
<html>
 +
<head></head>
 +
<body>
 +
   
 +
    <div class="container-fluid">
 +
<div class="row row-centered body_odd">
 +
<div class="col-xs-10 col-centered">
 +
<h1>Collaboration</h1>
 +
<p>UC Davis iGEM team has benefitted and supported the UC Santa Cruz iGEM team this year, through several skype calls, a meeting at the UC Bioengineering Symposium, and UC Davis hosting a delegation from UC Santa Cruz and collaborating on Human Practices work and sharing <em>Bacillus subtilis </em>plates.</p>
 +
<p>Key Points:</p>
 +
<ul class ="abstract">
 +
<li>Collaboration on Human Practices: Both teams followed Institutional Review Board review process and received exemption for our surveys.</li>
 +
<li>Collaboration on <em>Bacillus subtilis</em>: The UC Davis team shared several <em> subtilis </em>strains with permission from the Bacillus Genetic Stock Center, as well as protocols from both the stock center and advisers.</li>
 +
</ul>
 +
</div>
 +
</div>
 +
</div>
 +
<div class="container">
 +
<div class="row row-centered">
 +
<div class="col-xs-12 col-centered">
  
−
<div class="column full_size">
+
<h3>Human Practices</h3>
−
 
+
<p>The Human Practices Collaboration included a survey that complied with IRB regulations. To see these regulations in greater detail, please see the guide, including details about both UC Davis and UC Santa Cruz&rsquo;s respective IRB systems as well as our consent disclosures. We worked to ensure that both teams went through the required human subjects trainings and that these interventions were carried out to the highest ethical standards. We had multiple skype meetings, met up at the UC Bioengineering Symposium, and shared a meeting with some team members over the summer.</p>
−
 
+
<p>Between the two teams, we collected 44 responses. Some initial analysis is visible here:</p>
−
<p>
+
<br>
−
Sharing and collaboration are core values of iGEM. We encourage you to reach out and work with other teams on difficult problems that you can more easily solve together.
+
<div class = "centered">
−
</p>
+
<img src="https://static.igem.org/mediawiki/2016/7/79/T--UC_Davis--UCD16_colab1.png" class = "colabImg" alt="">
 +
<img src="https://static.igem.org/mediawiki/2016/6/62/T--UC_Davis--UCD16_colab2.png" class = "colabImg" alt="">
 
</div>
 
</div>
 +
<hr>
  
−
<div class="column half_size">
+
<p>The results are further analyzed throughout the wiki, and have provided an essential resource in coming to our policy conclusions.</p>
−
 
+
<p>Here are pictures of our teams meetings:</p>
−
<h4> Which other teams can we work with? </h4>
+
<div class="centered">
−
<p>  
+
<img src="https://static.igem.org/mediawiki/2016/f/f9/T--UC_Davis--UCD16_meet1.png" alt="" class="meetImg">
−
You can work with any other team in the competition, including software, hardware, high school and other tracks. You can also work with non-iGEM research groups, but they do not count towards the iGEM team collaboration silver medal criterion.
+
<img src="https://static.igem.org/mediawiki/2016/f/f4/T--UC_Davis--UCD16_meet2.png" alt="" class="meetImg">
−
</p>
+
<img src="https://static.igem.org/mediawiki/2016/f/f5/T--UC_Davis--UCD16_meet3.png" alt="" class="meetImg">
−
 
+
</div>
−
<p>
+
<p>&nbsp;</p>
−
In order to meet the silver medal criteria on helping another team, you must complete this page and detail the nature of your collaboration with another iGEM team.
+
<p>&nbsp;</p>
−
</p>
+
<p>&nbsp;</p>
−
 
+
<h3><em>Bacillus subtilis</em>:</h3>
 +
<p>&nbsp;</p>
 +
<p>The UC Davis team shared information and plates containing the following strains with the UC Santa Cruz team on their visit July 15<sup>th</sup>:<br /> </p>
 +
<p>Our team shared&nbsp;<strong>B. subtilis K07 - BGSC Accession # 1A1134</strong>. This strain was recently released and this K07 strain is generated from the commonly used laboratory host PY79. This strain has all it's seven associated proteases knocked out and is free from antibiotic resistance or integrated plasmids. This strain does produce spores however.</p>
 +
<p>We have also shared the&nbsp;<strong>B. subtilis PY79 - BGSC Accession # 1A747</strong>, which is the wildtype strain of the K07 protease knockout. We are selecting this strain so we have a control for comparison.&nbsp;</p>
 +
<p>A third strain which our team has shared is the&nbsp;<strong>B. subtilus spo0A3&nbsp;</strong>-&nbsp;<strong>BGSC Accession # 1S1.&nbsp;</strong>This strain comprises spo0A mutants, therefore they do not produce alkaline or neutral proteases. They also do not sporulate. The two most abundant secreted proteases are the alkaline protease (AprE) and the neutral protease (NprE) and are produced in the early stationary phase in normal bacillus. This mutant does not produce these proteases, however wall-associated proteases are still present. This strain is the result of mutations in the Spo0A locus and have normal antibiotic sensitivities. Note that Spo0A have reduced genetic competence, so it may be advisable to use electroporation to transform them.</p>
 +
<p>We also ordered and shared the following strains, which became available during the summer:</p>
 +
<ul>
 +
<li><strong>KO8 - </strong><strong>Protease-free strain knocked out in the BsuM restriction endonuclease (which will help with plasmid transformations) retaining wild-type levels of genetic competence (</strong><strong>available by July 4<sup>th</sup> or earlier</strong><strong>)</strong></li>
 +
<li><strong>KO9 - </strong><strong>Protease-free strain knocked out in the sigF gene which will be blocked at an early stage of sporulation and retains wild-type levels of genetic competence (</strong><strong>available by July 4<sup>th</sup> or earlier</strong><strong>)</strong></li>
 +
</ul>
 +
<p>We also shared protocols, specific codes, and information about promotors.</p>
 +
</div>
 +
<div class="col-xs-6 col-centered projLinks">
 +
<a href="https://2016.igem.org/Team:UC_Davis/Human_Practices" class="navBtn">Next: Human Practices</a>
 +
</div>
 +
</div>
 
</div>
 
</div>
  
  
  
−
<div class="column half_size">
 
−
<p>
 
−
Here are some suggestions for projects you could work on with other teams:
 
−
</p>
 
  
−
<ul>
+
    <div class = "container-fluid footer">
−
<li> Improve the function of another team's BioBrick Part or Device</li>
+
<div class="row row-centered">
−
<li> Characterize another team's part </li>
+
<div class="col-xs-8 col-centered centered">
−
<li> Debug a construct </li>
+
<p>Contact us at: ucdigem@gmail.com </p>
−
<li> Model or simulating another team's system </li>
+
</div>
−
<li> Test another team's software</li>
+
</div>
−
<li> Help build and test another team's hardware project</li>
+
−
<li> Mentor a high-school team</li>
+
−
</ul>
+
 
</div>
 
</div>
  
−
 
+
</body>
 
</html>
 
</html>

Latest revision as of 07:31, 19 October 2016

Cyantific: UC Davis iGEM 2016

Collaboration

UC Davis iGEM team has benefitted and supported the UC Santa Cruz iGEM team this year, through several skype calls, a meeting at the UC Bioengineering Symposium, and UC Davis hosting a delegation from UC Santa Cruz and collaborating on Human Practices work and sharing Bacillus subtilis plates.

Key Points:

  • Collaboration on Human Practices: Both teams followed Institutional Review Board review process and received exemption for our surveys.
  • Collaboration on Bacillus subtilis: The UC Davis team shared several subtilis strains with permission from the Bacillus Genetic Stock Center, as well as protocols from both the stock center and advisers.

Human Practices

The Human Practices Collaboration included a survey that complied with IRB regulations. To see these regulations in greater detail, please see the guide, including details about both UC Davis and UC Santa Cruz’s respective IRB systems as well as our consent disclosures. We worked to ensure that both teams went through the required human subjects trainings and that these interventions were carried out to the highest ethical standards. We had multiple skype meetings, met up at the UC Bioengineering Symposium, and shared a meeting with some team members over the summer.

Between the two teams, we collected 44 responses. Some initial analysis is visible here:


The results are further analyzed throughout the wiki, and have provided an essential resource in coming to our policy conclusions.

Here are pictures of our teams meetings:

 

 

 

Bacillus subtilis:

 

The UC Davis team shared information and plates containing the following strains with the UC Santa Cruz team on their visit July 15th:

Our team shared B. subtilis K07 - BGSC Accession # 1A1134. This strain was recently released and this K07 strain is generated from the commonly used laboratory host PY79. This strain has all it's seven associated proteases knocked out and is free from antibiotic resistance or integrated plasmids. This strain does produce spores however.

We have also shared the B. subtilis PY79 - BGSC Accession # 1A747, which is the wildtype strain of the K07 protease knockout. We are selecting this strain so we have a control for comparison. 

A third strain which our team has shared is the B. subtilus spo0A3 - BGSC Accession # 1S1. This strain comprises spo0A mutants, therefore they do not produce alkaline or neutral proteases. They also do not sporulate. The two most abundant secreted proteases are the alkaline protease (AprE) and the neutral protease (NprE) and are produced in the early stationary phase in normal bacillus. This mutant does not produce these proteases, however wall-associated proteases are still present. This strain is the result of mutations in the Spo0A locus and have normal antibiotic sensitivities. Note that Spo0A have reduced genetic competence, so it may be advisable to use electroporation to transform them.

We also ordered and shared the following strains, which became available during the summer:

  • KO8 - Protease-free strain knocked out in the BsuM restriction endonuclease (which will help with plasmid transformations) retaining wild-type levels of genetic competence (available by July 4th or earlier)
  • KO9 - Protease-free strain knocked out in the sigF gene which will be blocked at an early stage of sporulation and retains wild-type levels of genetic competence (available by July 4th or earlier)

We also shared protocols, specific codes, and information about promotors.

Next: Human Practices

Contact us at: ucdigem@gmail.com